Stock Mumak

Stock Profile

Nordex

European wind turbine manufacturer with rising profitability and strong leverage on the energy transition and electrification.

Stock Snapshot

Nordex Group Logo
Table HeaderTable Header
CompanyNordex SE
SectorEnergy
ThemeRenewable Energy / Wind Energy
Business ModelDevelopment, production, and maintenance of high-performance onshore turbine platforms to support global decarbonization.
ISINDE000A0D6554
Market Capitalization€10.31 billion
UMBRELLA StatusWatchlist

Nordex is a European manufacturer of wind turbines focusing on the development, production, and maintenance of onshore wind turbines.

The company operates globally, with a strong focus on Europe, and specializes in high-performance turbine platforms for large-scale deployment.

Unlike project developers, Nordex generates value through equipment sales, project implementation, and long-term service contracts, creating both cyclical and recurring revenue.

Key variable: Expansion of wind energy + pricing power + margin development

Price Performance (12 Months)

Mumak Score Card

Geopolitics

Industry

Fundamentals

Sentiment

Technical Analysis

Aktuelle Unternehmensmeldungen

Nordex SE
Valuation Analysis

Valuation Analysis: Nordex SE

ISIN: DE000A0D6554

Nordex SE is one of the leading European manufacturers of onshore wind turbines and benefits from the long-term trends of the energy transition, electrification, and decarbonization. The company possesses a strong market position, a high order backlog, and significantly improved fundamental data. Profitability is increasing, the balance sheet shows a solid liquidity base, and market sentiment remains positive. At the same time, risks exist due to regulatory changes, competitive pressure, and the long-term securing of margins. Overall, Nordex presents itself as a growth-oriented company with attractive prospects in the European wind energy market and an increasingly stable operational development.
Compass 4 out of 5
More research

Latest Portfolio Updates

Eli Lilly
Company Update

Eli Lilly – Q2 2026 Earnings Update

Eli Lilly grows rapidly in the second quarter of 2026: Revenue rises 48 percent, Mounjaro and Zepbound skyrocket, full-year guidance
Next Update
Bayer
Company Update

Bayer – Q2 2026 Earnings Update

Bayer increases revenue and operating earnings in Q2 2026 and confirms its full-year targets despite legal risks.
Next Update
Johnson & Johnson
Company Update

Bayer – Q2 2026 Earnings Update

Johnson & Johnson impresses with strong Q2 2026 figures, significantly increasing revenue and free cash flow while raising its guidance
Next Update
Weekly Update

Weekly Market Overview – July 27-August 2, 2026

The market overview shows why strong figures from Apple, Rheinmetall, and other companies are not always enough for price gains.
Next Update